<DOC>
	<DOCNO>NCT00083694</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Thalidomide patient leukemia .</brief_summary>
	<brief_title>Thalidomide Anti-Angiogenesis Therapy Relapsed Refractory Leukemia</brief_title>
	<detailed_description>Patients take Thalidomide tablet bedtime daily remission . The dose increase gradually modify accord side-effects . The drug give daily time complete remission long beneficial .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Diagnosis refractory relapse leukemia : acute leukemia , CML , CLLm MDS . Signed informed consent , include patient agree use safe contraceptive method treatment least 4 month treatment complete Serum creatinine &lt; = 2.5mg/dL Serum bilirubin &lt; = 2.5mg/dL Negative pregnancy test Age 18 year old Performance status &lt; = 3 Pregnant lactate woman Concurrent treatment cytotoxic chemotherapy , radiation History seizure , neurotoxicity , active CNS disease Serious infection control antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>relapse</keyword>
</DOC>